Transmission of fluoroquinolones resistance among multidrug-resistant tuberculosis in Shanghai, China: a retrospective population-based genomic epidemiology study

References

• World Health Organization. Global tuberculosis report 2022 [Internet]. Geneva: World Health Organization; 2022 [cited 2022 Oct 30]. Available from: https://apps.who.int/iris/handle/10665/363752.
   Google Scholar
• Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;S2213-2600(17):30079–6. doi:10.1016/S2213-2600(17)30079-6
   Google Scholar
• WHO consolidated guidelines on drug-resistant tuberculosis treatment [Internet]. Geneva: World Health Organization; 2019 [cited 2022 Jul 25]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK539517/.
   Google Scholar
• Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42:156–168. doi:10.1183/09031936.00134712
   PubMed Web of Science ®Google Scholar
• WHO consolidated guidelines on tuberculosis Module 4: treatment – Drug-resistant tuberculosis treatment, 2022 update [Internet]. Geneva: World Health Organization; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK588564/.
   Google Scholar
• Guo H, An J, Li S, et al. Transmission and resistome of extremely drug-resistant tuberculosis in Beijing, China: a retrospective population-based epidemiological study. J Infect Public Health. 2023;16:1193–1200. doi:10.1016/j.jiph.2023.05.020
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lu J, Wang Y, et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother. 2014;58:364–369. doi:10.1128/AAC.01228-13
   PubMed Web of Science ®Google Scholar
• Wang J-Y. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax. 2006;61:903–908. doi:10.1136/thx.2005.056887
   PubMed Web of Science ®Google Scholar
• WHO consolidated guidelines on tuberculosis: module 4: treatment – Drug-resistant tuberculosis treatment [Internet]. Geneva: World Health Organization; 2020 [cited 2022 Oct 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK558570/.
   Google Scholar
• Pang Y, Zhang Z, Wang Y, et al. Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000 to 2010. Antimicrob Agents Chemother. 2017;61:e02170–16. doi:10.1128/AAC.02170-16
   PubMed Web of Science ®Google Scholar
• Xia H, Zheng Y, Liu D, et al. Strong increase in moxifloxacin resistance rate among multidrug-resistant Mycobacterium tuberculosis isolates in China, 2007 to 2013. Microbiol Spectr. 2021;9:e0040921. doi:10.1128/Spectrum.00409-21
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366:2161–2170. doi:10.1056/NEJMoa1108789
   PubMed Web of Science ®Google Scholar
• Yang C, Lu L, Warren JL, et al. Internal migration and transmission dynamics of tuberculosis in Shanghai, China: an epidemiological, spatial, genomic analysis. Lancet Infect Dis. 2018;18:788–795. doi:10.1016/S1473-3099(18)30218-4
   PubMed Web of Science ®Google Scholar
• Li M, Guo M, Peng Y, et al. High proportion of tuberculosis transmission among social contacts in rural China: a 12-year prospective population-based genomic epidemiological study. Emerg Microbes Infect. 2022;11:2102–2111. doi:10.1080/22221751.2022.2112912
   PubMed Web of Science ®Google Scholar
• Yang C, Luo T, Shen X, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis. 2017;17:275–284. doi:10.1016/S1473-3099(16)30418-2
   PubMed Web of Science ®Google Scholar
• Luo T, Comas I, Luo D, et al. Southern east Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese. Proc Natl Acad Sci U S A. 2015;112:8136–8141. doi:10.1073/pnas.1424063112
   PubMed Web of Science ®Google Scholar
• Coll F, McNerney R, Guerra-Assunção JA, et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun. 2014;5:4812. doi:10.1038/ncomms5812
   PubMed Web of Science ®Google Scholar
• Coll F, McNerney R, Preston MD, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med. 2015;7:51. doi:10.1186/s13073-015-0164-0
   PubMed Web of Science ®Google Scholar
• Chinese Journal of Antituberculosis. Guidline for chemotherapy of drug resistant TB (2019 Simplified Version). Chin J Antituberc. 2019;41:1025–1073. doi:10.3969/j.issn.1000-6621.2019.10.001
   Google Scholar
• World Health Organization. Global tuberculosis report 2020 [Internet]. Geneva: World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/9789240013131.
   Google Scholar
• Zhao H, Wei L, Li H, et al. Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study. Lancet Infect Dis. 2021;21:847–857. doi:10.1016/S1473-3099(20)30596-X
   PubMed Web of Science ®Google Scholar
• Migliori GB, Langendam MW, D’Ambrosio L, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J. 2012;40:814–822. doi:10.1183/09031936.00036812
   PubMed Web of Science ®Google Scholar
• Ji L, Zhang L, Lu J, et al. Whole-genome sequencing for drug resistance profile prediction in multidrug-resistant Mycobacterium tuberculosis in Shenzhen. Chin J Antituberc. 2021;43:166. doi:10.3969/j.issn.1000-6621.2021.02.012
   Google Scholar
• Hu Y, Liu J, Shen J, et al. Prevalence and molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to fluoroquinolones in Chongqing. Chin J Antituberc. 2018;40:1060. doi:10.3969/j.issn.1000-6621.2018.10.006
   Google Scholar
• Shi W, Chu N. Resistance to fluoroquinolones and the influencing factors in patients with drug-resistant pulmonary tuberculosis. Chin J Antituberc. 2021;43:905. doi:10.3969/j.issn.1000-6621.2021.09.009
   Google Scholar
• He W, Tan Y, Liu C, et al. Drug-Resistant characteristics, genetic diversity, and transmission dynamics of rifampicin-resistant Mycobacterium tuberculosis in hunan, China, revealed by whole-genome sequencing. Microbiol Spectr. 2022;10:e0154321. doi:10.1128/spectrum.01543-21
   PubMed Web of Science ®Google Scholar
• Hu Y, Hoffner S, Wu L, et al. Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in rural China. Antimicrob Agents Chemother. 2013;57:3857–3863. doi:10.1128/AAC.00102-13
   PubMed Web of Science ®Google Scholar
• Liu C, Yang N, Wang Q, et al. Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital. Respirology. 2011;16:918–925. doi:10.1111/j.1440-1843.2011.01990.x
   PubMed Web of Science ®Google Scholar
• Chen T-C, Lu P-L, Lin C-Y, et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011;15:e211–e216. doi:10.1016/j.ijid.2010.11.008
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance inM. tuberculosis. N Engl J Med. 2003;349:1977–1978. doi:10.1056/NEJM200311133492023
   PubMed Web of Science ®Google Scholar
• Yip W, Fu H, Chen AT, et al. 10 years of health-care reform in China: progress and gaps in universal health coverage. Lancet. 2019;394:1192–1204. doi:10.1016/S0140-6736(19)32136-1
   PubMed Web of Science ®Google Scholar
• Lin H, Dyar OJ, Rosales-Klintz S, et al. Trends and patterns of antibiotic consumption in Shanghai municipality, China: a 6 year surveillance with sales records, 2009–14. J Antimicrob Chemother. 2016;71:1723–1729. doi:10.1093/jac/dkw013
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jiang Y, Yu C, et al. Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: a 10-year retrospective study. Front Public Health. 2022;10:990894. doi:10.3389/fpubh.2022.990894
   PubMed Web of Science ®Google Scholar
• Xiao H. Guidline for chemotherapy of drug resistant TB (2009). Chin J Antituberc. 2010;32:181–198. Available from: http://www.zgflzz.cn/CN/Y2010/V32/I04/181.
   Google Scholar
• Chinese Journal of Antituberculosis. Guidline for chemotherapy of drug resistant TB (2015). Chin J Antituberc. 2015;37:421–469. Available from: http://www.zgflzz.cn/CN/Y2015/V37/I5/421.
   Google Scholar